Open Access
Subscription Access
An Indication, Mechanism of Action, Administration, Adverse Effects, Contra Indications of Anti Retro Viral Therapy
Abstract
An initial HIV regimen usually consists of three HIV drugs from at least two different pharmacological classes. Despite not being a cure, this medication can prolong patients' lives and reduce the spread of HIV. Antiretroviral medication is now frequently used to reduce transmission in HIV-positive people who have an HIV-negative partner. In many regions of the world, the prevalence of HIV progression to AIDS has decreased due to the success of antiretroviral medication, making HIV a chronic illness. Research has verified that the three-drug regimen has led to a 60% to 80% reduction in hospitalization, death, and AIDS rates. A 90-90-90 strategy—90% HIV diagnosed, 90% on treatment, and 90% suppressed—is what the CDC intends to put into effect by 2030. This exercise explains HIV antiretroviral therapy's uses, contraindications, and indications while emphasizing the importance of the interprofessional team in improving patient safety.
References
Riddell, J., Amico, K. R., & Mayer, K. H. (2018). HIV preexposure prophylaxis: A review. JAMA, 319(12), 1261–1268. https://pubmed.ncbi.nlm.nih.gov/
Tanner, M. R., Miele, P., Carter, W., Valentine, S. S., Dunville, R., Kapogiannis, B. G., & Smith, D. K. (2020). Preexposure prophylaxis for prevention of HIV acquisition among adolescents: Clinical considerations, 2020. MMWR Recommendations and Reports, 69(3), 1–12. https://doi.org/10.15585/mmwr.rr6903a1
Cowan, E., Vail, R. M., Shah, S. S., Fine, S. M., McGowan, J. P., Merrick, S. T., ... & Norton, B. L. (2024). Diagnosis and management of acute HIV infection. Johns Hopkins University. https://pubmed.ncbi.nlm.nih.gov/
Saleska, J. L., Turner, A. N., Maierhofer, C., Clark, J., & Kwiek, J. J. (2018). Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low- and middle-income countries: A systematic review. Journal of Acquired Immune Deficiency Syndromes, 79(1), 1–9. https://pubmed.ncbi.nlm.nih.gov/
O'Donovan, K., & Emeto, T. I. (2018). Mother-to-child transmission of HIV in Australia and other high-income countries: Trends in perinatal exposure, demography and uptake of prevention strategies. Australian and New Zealand Journal of Obstetrics and Gynaecology, 58(5), 499–505. https://pubmed.ncbi.nlm.nih.gov/
Trovato, M., D’Apice, L., Prisco, A., & De Berardinis, P. (2018). HIV vaccination: A roadmap among advancements and concerns. International Journal of Molecular Sciences, 19(4), Article 1242. https://doi.org/10.3390/ijms19041242
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002). Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. MMWR Recommendations and Reports, 51(RR-7), 1–55. https://pubmed.ncbi.nlm.nih.gov/
Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., ... & Malik, A. (2021). A review: Mechanism of action of antiviral drugs. International Journal of Immunopathology and Pharmacology, 35, 20587384211002621. https://doi.org/10.1177/20587384211002621
Bettiker, R. L., Koren, D. E., & Jacobson, J. M. (2018). Ibalizumab. Current Opinion in HIV and AIDS, 13(4), 354–358. https://pubmed.ncbi.nlm.nih.gov/
Endalamaw, A., Tezera, N., Eshetie, S., Ambachew, S., & Habtewold, T. D. (2018). Adherence to highly active antiretroviral therapy among children in Ethiopia: A systematic review and meta-analysis. AIDS and Behavior, 22(8), 2513–2523. https://doi.org/10.1007/s10461-018-2126-4
Engler, K., Lènàrt, A., Lessard, D., Toupin, I., & Lebouché, B. (2018). Barriers to antiretroviral therapy adherence in developed countries: A qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure. AIDS Care, 30(sup1), 17–28. https://doi.org/10.1080/09540121.2018.1468016
National Institute of Diabetes and Digestive and Kidney Diseases. (2016). Abacavir. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548245/
National Institute of Diabetes and Digestive and Kidney Diseases. (2019). Lamivudine. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548245/
Leowattana, W. (2019). Antiviral drugs and acute kidney injury (AKI). Infectious Disorders - Drug Targets, 19(4), 375–382. https://pubmed.ncbi.nlm.nih.gov/
Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., ... & Currier, J. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): A multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet, 397(10281), 1276–1292. https://doi.org/10.1016/S0140-6736(21)00432-3
Gilleece, Y., & Krankowska, D. (2021). ART in pregnant women living with HIV. The Lancet, 397(10281), 1240–1241. https://pubmed.ncbi.nlm.nih.gov/
Ssentongo, P., Heilbrunn, E. S., Ssentongo, A. E., Advani, S., Chinchilli, V. M., Nunez, J. J., & Du, P. (2021). Epidemiology and outcomes of COVID-19 in HIV-infected individuals: A systematic review and meta-analysis. Scientific Reports, 11(1), 6283. https://doi.org/10.1038/s41598-021-85852-5
Levison, J., Weber, S., & Cohan, D. (2014). Breastfeeding and HIV-infected women in the United States: Harm reduction counseling strategies. Clinical Infectious Diseases, 59(2), 304–309. https://doi.org/10.1093/cid/ciu271
Nielsen-Saines, K., Watts, D. H., Veloso, V. G., Bryson, Y. J., João, E. C., Pilotto, J. H., ... & Mofenson, L. M. (2012). Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. New England Journal of Medicine, 366(25), 2368–2379. https://doi.org/10.1056/NEJMoa1108275
Anugulruengkitt, S., Suntarattiwong, P., Ounchanum, P., Srirompotong, U., Jantarabenjakul, W., Sophonphan, J., ... & Puthanakit, T. (2019). Safety of 6-week neonatal triple-combination antiretroviral postexposure prophylaxis in high-risk HIV-exposed infants. Pediatric Infectious Disease Journal, 38(10), 1045–1050. https://doi.org/10.1097/INF.0000000000002436
Ewald, H., Raatz, H., Boscacci, R., Furrer, H., Bucher, H. C., & Briel, M. (2015). Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database of Systematic Reviews, 2015(4), CD006150. https://doi.org/10.1002/14651858.CD006150.pub3
Guzman, N., & Vijayan, V. (2022). HIV-associated lipodystrophy. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK507882/
Chawla, A., Wang, C., Patton, C., Murray, M., Punekar, Y., de Ruiter, A., & Steinhart, C. (2018). A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infectious Diseases and Therapy, 7(2), 183–195. https://doi.org/10.1007/s40121-018-0190-0
Zanetti, H. R., Roever, L., Gonçalves, A., & Resende, E. S. (2018). Human immunodeficiency virus infection, antiretroviral therapy, and statin: A clinical update. Current Atherosclerosis Reports, 20(2), Article 9. https://doi.org/10.1007/s11883-018-0714-0
Dean, L. (2015). Abacavir therapy and HLA-B*57:01 genotype. In V. M. Pratt, S. A. Scott, M. Pirmohamed, B. Esquivel, B. L. Kattman, & A. J. Malheiro (Eds.), Medical Genetics Summaries. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK425182/
Refbacks
- There are currently no refbacks.